Comorbidities in Rheumatoid Arthritis: My Top Studies From EULAR 2020
  • CME

June 3-6, 2020; Virtual Meeting
My thoughts on recent studies of RA and ILD, fatigue, and cancer presented at the virtual EULAR 2020 E-Congress.
Paul Emery, MA, MD, FRCP
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: August 24, 2020 Expiration: August 23, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explore risk factors for RA comorbidities and outcomes associated with poor management


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Paul Emery, MA, MD, FRCP

Versus Arthritis, Professor of Rheumatology 
Leeds Institute of Rheumatic & Musculoskeletal Medicine
University of Leeds
Consultant, Rheumatology
Leeds Teaching Hospitals NHS Trust
Leeds, West Yorkshire

Paul Emery, MA, MD, FRCP, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, Lilly, and Novartis.


Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, primary care clinicians, and other healthcare providers who care for patients with RA.


The goal of this activity is to arm clinicians with the most current clinical and scientific advances in RA so that they can apply the latest evidence to optimally manage patients and achieve long-term remission.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 24, 2020, through August 23, 2021:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Released: December 23, 2020

Safety: Frequently asked questions from the CCO Webinar series, “ A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis”

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: December 18, 2020

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

From ACR/ARP 2020: expert-authored commentary on tapering RA therapy, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.